SCHEMBL12433870

SCHEMBL12433870

CCCCNc1cccc(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.51
UTS2R Q9UKP6 1/20 0.49
GBA1 P04062 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.46
HTR1A P08908 2/20 0.46
ADRA1D P25100 2/20 0.46
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
HPGD P15428 1/20 0.41
ABCB1 P08183 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11808662 0.90 CHRM2 (0.46) CHRM2UTS2RSMN1; SMN2HTR1AADRA1D
SCHEMBL6173269 0.84 CHRM2 (0.70) CHRM2UTS2RGBA1SMN1; SMN2HTR1A
SCHEMBL14226176 0.83 MAPT (0.44) CHRM2UTS2RGBA1SMN1; SMN2HTR1A
SCHEMBL9132120 0.82 SMN1; SMN2 (0.47) CHRM2SMN1; SMN2TSHRALDH1A1GAA
SCHEMBL27982786 0.81 TSHR (0.55) CHRM2GBA1SMN1; SMN2HTR1AADRA1D
SCHEMBL11496106 0.79 CHRM2 (0.73) CHRM2UTS2RGBA1SMN1; SMN2HTR1A
SCHEMBL24277324 0.79 CHRM2 (0.48) CHRM2SMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL24277459 0.79 CHRM2 (0.48) CHRM2SMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL27973788 0.78 NR3C1 (0.42) UTS2RGBA1SMN1; SMN2TSHRALDH1A1
SCHEMBL6933746 0.78 CHRM2 (0.76) CHRM2GBA1SMN1; SMN2HTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 US disclosed
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 US disclosed
EP-4154884-A1 ANTI-SARS-COV-2 DURG Oncolys BioPharma, Inc. (JP) 2023-03-29 EP disclosed
EP-2532652-B1 THERAPEUTIC AGENT FOR HEPATITIS C UNIV KAGOSHIMA (JP) 2014-11-12 EP disclosed
EP-2532652-B1 THERAPEUTIC AGENT FOR HEPATITIS C UNIV KAGOSHIMA (JP) 2014-11-12 EP disclosed
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C ONCOLYS BIOPHARMA, INC. (JP) 2012-12-13 US disclosed
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C ONCOLYS BIOPHARMA, INC. (JP) 2012-12-13 US disclosed
EP-2532652-A1 THERAPEUTIC AGENT FOR HEPATITIS C Kagoshima University (JP) 2012-12-12 EP disclosed
EP-2532652-A1 THERAPEUTIC AGENT FOR HEPATITIS C Kagoshima University (JP) 2012-12-12 EP disclosed
CN-102812007-A Therapeutic agent for hepatitis C UNIV KAGOSHIMA 2012-12-05 CN disclosed
WO-2011093483-A1 THERAPEUTIC AGENT FOR HEPATITIS C 国立大学法人鹿児島大学 (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, SARS1 CHRM2 692/4885UTS2R 2553/4885GBA1 1695/4885
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C HAVCR2, SLC10A1, FABP1 CHRM2 4844/4885UTS2R 3458/4885GBA1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.